Hsbc Holdings PLC Assembly Biosciences, Inc. Transaction History

Hsbc Holdings PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.09 - $20.4 $730 - $13,667	-670 Reduced 5.54%	11,413 $14,000
Q3 2022 Nov 14, 2022	SELL	$1.7 - $20.52 $4,090 - $49,371	-2,406 Reduced 16.61%	12,083 $20,000
Q2 2022 Aug 11, 2022	SELL	$1.35 - $2.29 $5,610 - $9,517	-4,156 Reduced 22.29%	14,489 $31,000
Q4 2021 Feb 11, 2022	BUY	$2.13 - $3.46 $39,713 - $64,511	18,645 New	18,645 $43,000
Q4 2019 Feb 14, 2020	SELL	$8.36 - $23.81 $235,409 - $670,465	-28,159 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$9.83 - $14.82 $276,802 - $417,316	28,159 New	28,159 $277,000
Q3 2018 Nov 13, 2018	SELL	$34.41 - $44.23 $359,687 - $462,336	-10,453 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$39.21 - $50.29 $370,769 - $475,542	-9,456 Reduced 47.5%	10,453 $410,000
Q1 2018 May 11, 2018	SELL	$41.7 - $64.16 $854,349 - $1.31 Million	-20,488 Reduced 50.72%	19,909 $978,000
Q4 2017 Feb 14, 2018	BUY	$28.58 - $49.91 $1.15 Million - $2.02 Million	40,397	40,397 $1.83 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.